TABLE 1.

Characteristics of included studies.

References	Country	Study design	Type	Number of patients	Age (years)	Gender (F/M)	MELD score	APACHE II	SOFA score
Yu et al. (26)	China	Prospective	RRT	145	59 (48-72)	53/92	NR	28 (23-35)	NR
Slowinski et al. (13)	Germany	Prospective	RRT	85	63 ± 15	25/60	NR	NR	14 ± 3
Lahmer et al. (12)	Germany	Prospective	RRT	24	59 (29-73)	4/20	35 (25-40)	33 (24-40)	16 (8-19)
De Vico et al. (27)	Italy	Prospective	RRT	15	67.4 ± 11.9	5/10	NR	NR	NR
Schultheiß et al. (11)	Germany	Prospective	RRT	28	57 ± 11	8/20	36 ± 8.8	NR	NR
Pourcine et al. (28)	France	Retrospective	RRT	41	67 (57-73)	19/22	27 (18-42)	NR	NR
Rhee et al. (29)	United States	Retrospective	RRT	32	58.2 ± 14.4	9/23	NR	NR	14.9 ± 3.3
Yu et al. (30)	China	Retrospective	RRT	41	52.49 ± 15.62	22/41	29.78 ± 6.93	17.12 ± 4.30	11.44 ± 4.04
Klingele et al. (41)	Germany	Retrospective	RRT	69	59.1 ± 12.4	22/47	19.7 ± 9.6	NR	NR
Sponholz et al. (31)	Germany	Retrospective	RRT	89	54 (46.5-59.5)	31/58	NR	23 (19-30)	NR
Saner et al. (32)	Germany	Retrospective	RRT	68	47.1 ± 11.8	28/40	NR	17.7 ± 3.7	23.1 ± 9.1
Durão et al. (33)	Brazil	Retrospective	RRT	143	66 ± 16	59/84	NR	27.3 ± 9.3	NR
Ma et al. (34)	China	Prospective	PE	54	50.0 ± 11.3	13/41	NR	NR	NR
Berber et al. (35)	Turkey	Retrospective	PE	59	42 (22-84)	29/30	NR	NR	NR
Maheshwari et al. (36)	India	Retrospective	PE	45	38 (27-68)	14/31	NR	NR	NR
Meijers et al. (37)	Belgium	Prospective	MARS	10	55 ± 10	NR	NR	NR	NR
Falkensteiner et al. (38)	Germany	Retrospective	MARS	49	59 (45.5-64.0)	18/31	32 (18.0-38.0)	24 (20.0-30.0)	11 (8-13.5)
Faybik et al. (39)	Austria	Retrospective	MARS	20	43.5 (23.5-56.5)	NR	31 (26.5-40)	NR	14.2 (4-20)
Yonekawa et al. (40)	Japan	Prospective	RRT + PE	9	65 (54-78)	2/7	NR	NR	NR

RRT, renal replacement therapy; MARS, molecular adsorbent recirculation system; PE, plasma exchange; NR, not reported; MELD, model for end-stage liver disease; APACHE, acute physiology and chronic health evaluation; SOFA, Sequential Organ Failure Assessment.